

2,500 PDX *in vivo* tumor models with many in passage and available for efficacy testing.

HuPrime models are well-characterized and annotated with expression profiling (RNAseq and U219) and gene copy number (WES and SNP6) data. MicroRNA and hotspot analysis is also available.

- Large, diverse collection of PDX models from US, European, and Asian populations covering over 35 cancer types
- Models derived from both treatment naïve and pretreated patients
- Many PDX samples are derived from metastatic lesions
- PDX models of both innate and acquired resistance

- PDX collection contains models with relevant mutations represented in patient populations
- Unique models of specific disease pathways for targeted therapy such as RET, ALK, EGFR, MET, IDH, RSPO, and HER2
- Unique collections of underrepresented indications, including GIST, prostate cancer, and AML
- Curated, online, searchable database (HuBase) of phenotypic and genotypic data, patient information, growth curves, and standard of care treatment data













